A detailed history of Vestal Point Capital, LP transactions in Cytokinetics Inc stock. As of the latest transaction made, Vestal Point Capital, LP holds 2,075,000 shares of CYTK stock, worth $107 Million. This represents 8.38% of its overall portfolio holdings.

Number of Shares
2,075,000
Previous 2,150,000 3.49%
Holding current value
$107 Million
Previous $151 Billion 25.42%
% of portfolio
8.38%
Previous 12.47%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$47.86 - $75.05 $3.59 Million - $5.63 Million
-75,000 Reduced 3.49%
2,075,000 $112 Billion
Q1 2024

May 13, 2024

BUY
$63.75 - $108.06 $134 Million - $227 Million
2,100,000 Added 4200.0%
2,150,000 $151 Billion
Q4 2023

Feb 13, 2024

BUY
$26.88 - $83.49 $1.34 Million - $4.17 Million
50,000 New
50,000 $4.17 Billion

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.85B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Vestal Point Capital, LP Portfolio

Follow Vestal Point Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vestal Point Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Vestal Point Capital, LP with notifications on news.